Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

21 Mar 2026, 08:28 by Amy Steele · The Cerbat Gem

Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.13), FiscalAI reports.

Here are the key takeaways from Relmada Therapeutics’ conference call:

NDV‑01 phase II 12‑month data reported a 76% 12‑month complete response rate overall and 80% in BCG‑unresponsive patients (CR anytime 95% overall, 94% BCG‑unresponsive) with a favorable safety profile (no progression to muscle‑invasive disease, no cystectomies, no grade ≥3 treatment‑related AEs).
Relmada secured FDA alignment on a two‑pathway registrational strategy and plans to initiate the phase III RESCUE program mid‑2026—an adjuvant randomized trial in intermediate‑risk NMIBC (vs observation) and a single‑arm BCG‑unresponsive trial, with initial 3‑month readouts expected by end‑2026.
The company completed a $160M private financing and reported $93M cash at year‑end 2025, which management states provides runway through 2029 and to complete the NDV‑01 phase III program.
Q4 2025 results showed a net loss of $19.9M ($0.27/sh) and higher operating cash burn (net cash used in operations $14.6M in Q4) with increased G&A expenses, reflecting continued development‑stage losses.
Sepranolone (a GABA‑modulating steroid antagonist) is advancing toward a mid‑2026 proof‑of‑concept trial in Prader‑Willi, but these are company forward‑looking statements and remain subject to clinical and regulatory risks.

Relmada Therapeutics Stock Performance

RLMD stock opened at $6.07 on Friday. The company has a market capitalization of $445.14 million, a P/E ratio of -4.19 and a beta of 0.72. The company has a fifty day moving average price of $4.50 and a 200-day moving average price of $3.56. Relmada Therapeutics has a 52-week low of $0.24 and a 52-week high of $7.51.

Analyst Ratings Changes

Several research firms recently weighed in on RLMD. Zacks Research raised shares of Relmada Therapeutics to a “hold” rating in a research report on Tuesday, January 27th. Mizuho raised their target price on shares of Relmada Therapeutics from $10.00 to $19.00 and gave the company an “outperform” rating in a report on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Relmada Therapeutics in a research report on Wednesday, January 28th. Lucid Cap Mkts raised shares of Relmada Therapeutics to a “strong-buy” rating in a report on Monday, March 2nd. Finally, Jefferies Financial Group assumed coverage on shares of Relmada Therapeutics in a research report on Monday, December 22nd. They set a “buy” rating and a $9.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Relmada Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.00.

Check Out Our Latest Report on Relmada Therapeutics

Institutional Trading of Relmada Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janus Henderson Group PLC bought a new position in Relmada Therapeutics during the 4th quarter worth $35,041,000. Squadron Capital Management LLC acquired a new position in Relmada Therapeutics during the 4th quarter worth about $32,361,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Relmada Therapeutics in the 4th quarter valued at about $20,624,000. Marshall Wace LLP increased its stake in shares of Relmada Therapeutics by 1,072.4% in the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock valued at $15,406,000 after buying an additional 2,917,609 shares during the period. Finally, Orbimed Advisors LLC acquired a new stake in shares of Relmada Therapeutics in the fourth quarter valued at about $12,609,000. 45.24% of the stock is currently owned by institutional investors and hedge funds.

Key Relmada Therapeutics News

Here are the key news stories impacting Relmada Therapeutics this week:

Positive Sentiment: Mizuho raised its price target sharply to $19 and upgraded RLMD to “Outperform,” implying large upside from current levels — this is a clear buy-side catalyst that can drive buying interest and re-rate sentiment. Read More.
Positive Sentiment: Company press release highlights audited Q4 and full‑year 2025 results and a corporate update describing “significant progress across its pipeline” (ongoing clinical and strategic milestones). Pipeline advancement tends to support longer-term valuation for clinical-stage biotech. Read More.
Neutral Sentiment: Earnings call transcripts and highlights from multiple outlets provide management commentary on strategy, program timelines and cash runway; useful for investors parsing catalysts but not an immediate market mover on their own. Review the call transcript for details on enrollment, milestones and guidance. Read More.
Negative Sentiment: Relmada reported Q4 EPS of ($0.27), missing consensus (~($0.14)) by ~$0.13 — a near-term negative that highlights continued operating losses and may pressure sentiment until clearer revenue or milestone offsets emerge. Read More.

Relmada Therapeutics Company Profile

(Get Free Report)

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.